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A B S T R A C T
In this study a carrier-free dry powder inhalation (DPI) containing L-arginine (ARG) was de-
veloped. As such, it is proposed that ARG could be used for adjunctive treatment of cystic
fibrosis and/or tuberculosis. Various processing methods were used to manufacture high-
dose formulation batches consisting various amounts of ARG and excipients.The formulations
were evaluated using several analytical methods to assess suitability for further investiga-
tion. Several batches had enhanced in vitro aerolization properties. Significant future challenges
include the highly hygroscopic nature of unformulated ARG powder and identifying the scale
of dose of ARG required to achieve the response in lungs.
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1. Introduction
1.1. Potential opportunities for inhaled arginine
The pulmonary delivery of drugs represents a complex deliv-
ery challenge [1]; however, the advantages of this approach are
well known and include rapid onset of action and delivery site
targeting to minimize the dose [2]. For example an oral dose
of bronchodilator may take 2–3 h to be effective, while an
inhaled dose usually takes approximately 15–30 min [3]. More
recently, newmethods and materials for the formulation of dry
powder particles suitable for highly-efficient high-dose pul-
monary delivery have become available. High lung doses are
traditionally delivered via a nebulizer; however, nebulizers are
mostly restricted to use in hospital and ambulatory care set-
tings due to their large size and expense. In addition, nebulized
aerosols need to be delivered continuously over an extended
period of time to provide a high dose. High dose delivery via
a dry powder inhaler (DPI) would offer advantages in terms of
size, ease of use, convenience and efficiency of delivery.
L-arginine (ARG) (Fig. 1) is one of the most common amino
acids in nature. It is a semiessential or conditionally essen-
tial amino acid, depending on the developmental stage and
health status of the individual [4]. ARG is used therapeuti-
cally in a range of human conditions [5] due to its conversion
to nitric oxide (NO). NO mediates many human physiological
processes including smooth muscle relaxation, bronchodilation
[6], innate immune responses (direct mycobactericidal effect
on bacterial cells) and cell-mediated immune effects (en-
hanced expression of theT cell receptor CD3ζ) [7].This molecule
has a crucial role specifically in human immune defense against
Mycobacterium tuberculosis [7–9].
ARG shows promise as an inhaled therapeutic in cystic fi-
brosis (CF), a condition characterized by low pulmonary nitric
oxide (NO) production [10–14]. CF is an autosomal recessive
genetic disorder with highmorbidity in the paediatric and young
adult populations mostly due to chronic pulmonary infec-
tions. In several studies by Grasemann et al. [6,15] measureable
pulmonary benefits in CF patients have been documented after
targeted delivery of ARG to the lungs, whereby high-dose ARG
was administered via nebulizer. The concentration of NO in
exhaled air and forced expiratory volume in 1 second were both
increased. ARG was well tolerated by paediatric patients [15].
Oral ARG has been trialled as an adjunctive therapy in people
with pulmonary tuberculosis [16–19] in which, like CF, low pul-
monary NO production has been documented [6]. Despite some
initial promising findings [18,19], there were no benefits of ARG
in the most recent trial using the highest ARG dose, and fur-
thermore, oral ARG did not achieve any measurable increase
in the concentration of NO in exhaled air [17]. It has been hy-
pothesized that with higher doses, or targeted delivery to
airways, ARG might be capable of measurably increasing pul-
monary NO bioavailability, and thereby improving macrophage
killing of tuberculosis bacilli.Therefore, inhaledARGmerits con-
sideration as a means to generate elevated local pulmonary
NO.
Proposed adjunctive therapies for CF or tuberculosis must
be safe and effective, tolerated by adults and children, and also
low-cost.Thus L-arginine is appealing as an investigational ad-
junctive agent in these conditions.
This study investigates possible formulation and process-
ing approaches to enable the high dose delivery of ARG via a
DPI.
1.2. Creating high-dose inhaled formulations
The principal criterion for a DPI is the ability of the system to
efficiently and reproducibly deliver active pharmaceutical in-
gredient (API) to the target parts of the respiratory track to
enable the required response. Particle aerodynamic size is the
most important design variable for a DPI formulation [1]. To
reach the peripheral airways, where drug is most efficiently
absorbed, particles need to be below about 5 μm aerody-
namic diameter [20]. According to Stokes Law, particles larger
than 5 μm usually deposit in the oral cavity or pharynx by im-
paction and so do not reach the peripheral target. In addition,
some deposition models suggest that particles smaller than
0.5 μm may not deposit efficiently, depending on the patient
breathing pattern, and may be exhaled.
Most current DPI formulations consist of micronized drug
blended with larger carrier particles, which enhance flow and
aid in dispersion. However, inefficient drug/carrier separa-
tion is one of the main reasons for the relatively low deep lung
deposition efficiency encountered with DPIs [21]. Also high dose
delivery is a challenge in the performance of DPIs with carrier
particles.Thus, in some cases it is preferred for no carrier par-
ticles to be present in the powder administered [22,23].
Product manufacture requires that powders have a suffi-
cient flowability so that capsules for DPI devices can be easily
and efficiently filled. Similarly, efficient aerosol delivery upon
actuation of the DPI requires the formulation to have effec-
tive fluidization, such that it re-suspends and is entrained from
the device and that effective de-aggregation occurs such that
the API is detached from its carriers and/or itself once re-
suspended. However, micron-sized particles, particularly those
resulting from high-energy operations such as jet milling, have
high surface areas and tend to have high surface energies,
which result in typically very poor flow and fluidization and
a high disposition to form strong aggregates. Flow properties
of material are influenced for example by particle size and size
distribution, surface roughness and particle morphology, surface
energy and also moisture/capillary effects [24]. Excipients can
be used to reduce the cohesive nature of the API, and so
enhance aerosolization efficiency by occupying the high-
energy “sticky” surface sites of the drug particles. However, the
range of effective potential excipients is limited for example
to compounds that are endogenous, non-irritant and can easily
be metabolized or cleared, and not requiring extensive toxi-
cology evaluation. Excipients can be modified or combined
within particle engineered structures with the API.Fig. 1 – Molecular structure of L-arginine.
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In addition, the relative humidity (RH) of air may have an
impact on the flowability of small particles, especially with hy-
groscopic powders. The term ‘hygroscopicity’ describes the
ability of a solid to take up and retain water [25]. Moisture
uptake and loss due to changes in RH can result in local dis-
solution and recrystallization, leading to irreversible aggregation
through solid bridge formation, which can adversely affect lung
deposition [26–30]. Hygroscopicity can also alter the adhesive
and cohesive properties, or, in more extreme situations, sub-
stantially increase particle size [31] or even cause dissolution.
Excipients that modify the hygroscopic properties of a drugmay
need to be considered [1]. It has been indicated that the pres-
ence of hydrophobic additives may reduce the hygroscopic
growth rate, the instantaneous particle size and by inference
the deposition of aerosols in the lungs [32]. Several ap-
proaches have been proposed to produce micronized particles
with hydrophobic surfaces that may reduce the problems
present for hygroscopic drug particles [32–35].
In order to obtain a drug particle size in the respirable range,
in most cases a size-reducing step is needed.There are several
options for reducing the particle size, and it may be neces-
sary to evaluate several methods to find the one most suited
for the specific drug, dose and delivery environment.
Milling techniques are widely used methods in pharma-
ceutical industry. Respirable-sized particles are traditionally
prepared by jet-milling techniques. Jet milling reduces par-
ticle size via high-velocity particle–particle collisions. Particles
prepared by jet-milling can be highly electrostatically charged,
comprise fractured crystals, and there is only a limited control
over size, shape, and morphology of the produced particles [36].
Ball milling is an alternative micronization technique. Ball
milling processes are less readily scalable and prone to media
contamination, which is why they are mainly limited to the
laboratory scale.
Mechanofusion, i.e. dry powder coating, is an alternative dry
mechanical process step used to improve the flow of cohe-
sive powders by modifying their inter-particle interactions.
Mechanofusion process is described in detail by Zhou et al. [37].
The process imparts a considerable amount of thermo-
mechanical energy that coats the guest material onto the
exposed surfaces of the host particles [38,39]. The mecha-
nism of mechanofusion process is complex and is not well
understood [40–42]. However, unlike general milling and co-
milling processes, the energy input is more controlled and the
process can be tuned to encourage coating but not size reduc-
tion [34]. Begat et al. [43] showed successful coating of
micronized drug to achieve substantially enhanced drug aero-
solization performance using additives such as magnesium
stearate.Mechanical dry coating has also been successfully used
for suppressing the hygroscopicity of materials [44,45].
Spray drying is growing in popularity as an alternative
method for production of inhalable dry powder formulations
due to its adaptability, cost-effectiveness and potential for
complex particle engineering and scalability [46]. In spray-
drying process the drug is dissolved in solvent, usually water,
and sprayed as fine mist into a heated expansion chamber.The
droplets dry, leaving behind tiny particles of drug that are col-
lected. Spray dried particles can be formulated to contain
various ingredients by adjusting the content and nature of the
feed solution [47]. Thus, excipients can be incorporated to
engineer the properties of the final powder. Co-spray drying
a solution containing two drugs is a potential alternative to
produce particles with uniform drug composition [48]. Thus
spray drying is an attractive method for the manufacture of
novel, sophisticated aerosol formulations.
The amino acid L-leucine is known to be an effective par-
ticle formation agent that substantially improves the processing
yields of the spray dried formulations and forms high-rugosity
particles [47]. It also has an ability to reduce cohesion and
therefore enhance aerosolization efficiency and delivery
[22,33,35,47–58]. Isomalt is a sugar alcohol which is used es-
pecially in hard candies but also in pharmaceutical tablets as
an excipient due to its non-hygroscopic nature. Isomalt has
Generally Recognized as Safe (GRAS) status but currently is not
approved for pulmonary administration but only for oral tablets
by the U S Food and Drug Administration (FDA). In this study
isomalt was used to protect ARG frommoisture effects in spray
dried formulations.
For each particle size-reducing and surface-modifying tech-
nique it is important to consider a range of practical issues:
for example, material effects, efficiency, reliability, scale, cost,
supply chain and availability, etc. Spray drying offers greater
flexibility and the possibility of morphology control but the yield
can be low at small scale and the process is relatively expen-
sive. Most commonly, milling remains the process of choice
for micronizing drug because it is commonly available, easier
to scale up, and is less expensive. However, it is well docu-
mented in the literature that milling can cause disruption of
the crystal structure, leading to various degrees of disorder
[59–62] and has the potential to influence electrostatic charge,
flow, cohesiveness and polymorphic form including the amor-
phous form [63–65].
The aim of this study was to evaluate the effectiveness of
these potential processing options in the context of develop-
ing a DPI for high-dose ARG delivery where requirements for
the final DPI formulation focus are represented as follows:
(1) Formulation should create a suitable aerosol to reach the
lower parts of the respiratory track efficiently
(2) The amount of API has to be as high as possible, reflect-
ing the anticipated large multi-milligram dose of API
(3) The amount of excipients has to be as low as possible
and powder bulk density is suitable to fit to the admin-
istration vessel (e.g. capsule for a DPI)
(4) Materials should be well-tolerated in the lungs and ap-
proved or approvable by suitable authorities
(5) The materials and the manufacturing process have to
be cost-effective and efficient at scale
(6) The product should be physically and chemically stable
in humid conditions to ensure suitability in all climac-
tic conditions
2. Materials and methods
2.1. Materials
L-arginine (ARG, Sigma-Aldrich Chemicals, Castle Hill, Austra-
lia) was the active ingredient used in this study. Isomalt (food
grade, Cake Deco,Melbourne,Australia), which is a disaccharide
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consisting of glucose and mannitol, was used in spray drying
as an excipient. Also L-leucine (Leu, Sigma-Aldrich Chemi-
cals, Castle Hill, Australia) and magnesium stearate (MS, 2255,
Mallinckrodt Specialty Chemicals, Dublin, Ireland) were used
as excipients.
2.2. Methods
This formulation study involved several processingmethods.The
Design of Experiment (DoE) and nomenclature are repre-
sented in Fig. 2. UnprocessedARG [ARG(raw)] was jetmilled alone
[JM(ARG)] and thereafter either ball milled ormechanofusedwith
MS or Leu. ARG was also co-jet milled with Leu (ARG11) or MS
(ARG12) and then ball milled or mechanofused. ARG was also
spray driedwith isomalt and Leu [SD(ARG)]. Furthermore SD(ARG)
was mechanofused with MS (ARG10). In addition,ARG(raw) was
studied as a reference.
2.2.1. Jet milling
Pure L-arginine [ARG(raw)] was jet milled to decrease the par-
ticle size. All of JM(ARG) used in this study was produced in
one batch, avoiding potential batch differences. Thus, the
batches fromARG1 to ARG9 were jet milled as a single primary
source, prior to ball milling or mechanofusion. In addition,
ARG11 and ARG12 were co-jet milled with excipients Leu (20%
w/w) and MS (2% w/w), respectively.
The powders were jet milled using a Spiral Jet Mill 50 AS
(HosokawaAlpine AG,Augsburg, Germany).ARG and MS or ARG
and Leu were manually mixed before the jet milling by tum-
bling for several minutes in a glass vessel. A grinding gas
pressure of 7 bar and an injector gas pressure of 7.5 bar were
used during themilling.The powder was fed to the jet mill using
a vibrating feeder (Retsch Type DR100/75 Rinne rechts, Retsch
GmbH, Haan, Germany).
2.2.2. Mechanofusion
Mechanofusion was carried out in AMS-Mini Mechanofusion
system (Hosokawa Micron Corporation, Osaka, Japan) with
Nobilta rotor blade (Hosokawa Micron Corporation, Osaka,
Japan).The jet-milled ARG powder was mechanofused with ex-
cipients to manufacture batches ARG3 (2% MS), ARG4 (20% Leu)
and ARG9 (20% MS). In addition batches ARG6 and ARG8 were
mechanofused after co-jet-milling with excipients (excipi-
ents were added before jet-milling so no excipients were added
for mechanofusion). Finally ARG10 was mechanofused after
spray drying without added excipients in the mechanofusion
phase (Fig. 2). The powders were premixed in the mechano-
fusion vessel for 5 min at 500 rpm. After premixing, the vessel
was opened and the walls and lid were cleaned with a plastic
brush. The speed of the blade was then increased from 0 to
4000 rpm for 1 min and was kept constant after the ramping
for 10 min. Nitrogen flow rate was approximately 2.5 l/min and
cold water was kept flowing through the incorporated water
jacket to prevent the vessel temperature from exceeding 25 °C.
The sample size was 10 g.
2.2.3. Ball milling
The jet-milled ARG powder was ball milled with excipients to
manufacture batches ARG1 (20% Leu) and ARG2 (2% MS). In
addition batches ARG5 and ARG7 were ball milled after co-jet-
milling with excipients (excipients were added before jet-
milling so no excipients were added for ball milling) (Fig. 2).
Pulverisette 6 planetary mill (Fritsh Pulverisette, Idar Oberstein,
Germany) was used for ball milling. The used bowl size was
250 ml and approximately 100 stainless steel balls (400 g) with
diameter of 10 mm were used. Sample (10 g) was weighed on
top of the balls in the bowl. Milling speed of 500 rpm was used
for 3 min and after that the powder was separated from the
balls with a sieve (size 300 μm).
2.2.4. Spray drying
An aqueous solution containing ARG, isomalt and Leu in w/w
ratio 2:2:1 was dissolved in Milli-Q water so that a total 2.5%
solids (w/w) concentration was achieved.This was mixed with
a magnetic stirrer until the solution became clear. Spray-
drying was conducted in a Buchi 190 spray dryer (Buchi,
Labortechnik AG, Flawil, Switzerland) using the following stan-
dard operating conditions: air flow 800 l/h, solution flow
6.7 ml/min and aspirator pressure −84 mbar.These values lead
to an outlet temperature of 70 (±5) °C. The powder was har-
vested in a humidity controlled space (RH 20 ± 2%, T = 23 °C).
This spray dried batch was identified as SD(ARG). The pro-
cessing yield was defined as the percentage of the mass of
spray-dried powder recovered (Mrecovered) compared to the mass
of total solid loading (Mtotal) in the initial feed solution (Eq. 1):
Yield
M
M
recovered
total
% = × 100 (1)
Fig. 2 – Design of Experiments (DoE) and nomenclature.
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2.2.5. Particle size
Particle size distributions (PSD) were measured by laser dif-
fraction using a Malvern Mastersizer system (Mastersizer 2000,
Malvern Instruments Ltd., Malvern, UK) attached to a dry
module (Scirocco, Malvern Instruments Ltd., Malvern, UK), and
under optimized conditions, an inlet air pressure of 1.5 bar was
used. Measurements were made in triplicate. The measure-
ments were carried out at 50 ± 5% RH. The results are
represented as d10, d50 and d90 values. d values are used as
a quality control tool to provide a screening indication only
to understand whether PSD is broadly within the respirable
range.
2.2.6. Density and flowability
Poured density (ρp) and tapped density (ρt) were measured from
the powders.The poured volume was measured by pouring ap-
proximately 10 g of the sample slowly into a 50 ml measuring
cylinder (Glassco) via a funnel at a fixed height. ρp was calcu-
lated by dividing the mass of the sample with the poured
volume.The cylinder was then attached to an automatic tapper
(Autotap AT-2, Quantachrome Instruments, Boynton Beach, FL,
USA) and tapped until the difference in the volume between
these two taps was less than 2 ml typically 1250 taps (Ph. Eur.).
The ρt was determined after tapping by dividing the mass of
the sample with the tapped volume. Each sample was mea-
sured in triplicate. The Carr index (CI) [66] (Eq. 2) and the
Hausner ratio (HR) [67] (Eq. 3) were calculated from ρp and ρt:
CI t p
t
=
−ρ ρ
ρ
, (2)
HR t
p
=
ρ
ρ
, (3)
2.2.7. Cohesion
The cohesion of each sample was characterized using the
Freeman FT4 rheometer (FreemanTechnology,Tewkesbury, UK)
using a 1 ml shear cell. In the shear mode, a shear head was
attached to the powder rheometer, and shear stress was mea-
sured with respect to the normal stress for a given consolidating
stress. A fuller description of the principles of shear cell testing
was described by Schwedes [68]. For this application a method
described by Zhou et al. [37] was used.The cohesion value pro-
vides a measure of the cohesive inter-particle forces within the
bed, and hence, a higher value corresponds to a more cohe-
sive powder [68]. The FT4 measurements were carried out
between 39% and 42% RH.
2.2.8. Morphology
Scanning electron microscopy (SEM) was used to investigate
the particle size, shape and morphology of the samples. The
powder was sprinkled on top of double-sided carbon tape and
loose particles were removed by tapping the sample stub.
Samples were prepared in 20 °C and 25 ± 2% RH. Samples were
then coated with platinum in vacuum evaporation coater (Gun
Quorum Q150TS, Quorum Technologies, Laughton, UK). The
images were acquired using an acceleration voltage of 10 kV
and magnification from 100× to 10,000× or 20,000× with FEI
Quanta 250 FEG (FEI Inc., Hillsboro, OR, USA).
2.2.9. In vitro powder aerosolization
The in vitro powder aerosolization performance was deter-
mined using an abbreviated Andersen cascade impactor (ACI)
system (Copley Scientific Limited, Nottingham, UK) config-
ured as described and validated previously [47,69]. The
Monodose inhaler (Miat S. p. A., Milan, Italy) was used as the
aerosol dispersion device. It consisted of, from top to bottom,
the throat piece, pre-separator (with 10 ml of water), stage 0,
an impaction plate coated with a surfactant (Brij-35), stage F
containing a filter paper, and the bottom plate.The cut-off aero-
dynamic diameter of powders deposited on the filter paper
using this configuration at a flow rate of 90 l/min is approxi-
mately 4.7 μm according to the above literature. Approximately
20 mg of samples was weighed and filled into size 3 hydro-
xypropyl methylcellulose (HPMC) capsules (Capsugel, Peapack,
NJ, USA).The capsule filling was performed in a humidity con-
trolled environment (RH 20 ± 2%, T = 23 °C), and filled capsules
were subsequently protected from moisture until firing.
The actuations were performed at 23 °C, 50 ± 5% RH. Each
capsule was actuated from the inhaler over 6 s for each mea-
surement. Measurements were made in triplicate. Fine particle
dose (FPD) and fine particle fraction (FPF) were calculated as
a percentage of the emitted dose (ED). FPD refers to the mass
of drug in the potential deposition size range. In this study the
effective cut-off diameter was 4.7 μm. FPF is the fraction of an
aerosol that is in a size range (in this study 4.7 μm) with the
potential to penetrate and deposit in the airways. ED and the
amount of powder deposited on the filter paper were deter-
mined gravimetrically, an approach that is valid because no
separate carrier particles were used in this formulation and
stage loadings were sufficient to allow suitable measurement
[47].
2.2.10. Dynamic vapour sorption and hygroscopicity
Dynamic vapour sorption (DVS) was used to evaluate the hy-
groscopicity of the powders.Themeasurements were performed
using the DVS Intrinsic SMS (Surface Measurements Systems,
London, UK) and were conducted under nitrogen gas at tem-
perature of 25 °C. RH cycle 0 – 50 – 75 – 0% RH was employed.
Time intervals were 70 – 140 – 110 – 100 min, respectively.
Sample size varied from 16 mg to 20 mg.
Moisture uptake (Mt) was calculated from the weight (mw)
recorded at time t = 320 min (at 75% RH) and the weight (md)
of the dried sample at time t = 70 min (at 0% RH) (Eq. 4):
M
m m
m
t
w d
d
= ×
−
100 (4)
2.2.11. Principal component analysis
Altogether 11 main results parameters were analysed using
principal component analysis (PCA). These were moisture
uptake (Mt), particle sizes (d10, d50, d90), densities (bulk and
tapped), Hausner ratio (HR), Carr’s index (CI), cohesion, FPD and
FPF. PCA categorized data so that similar samples are plotted
at the same area in the score scatter plot to show the corre-
lation between observations (in this case different batches). A
loadings plot is used to show the relative influence of each vari-
able (in this case different results parameters such as d10
or FPD) on the scores. The interpretation of the PCA at
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pharmaceutical applications is described in more detail by
Rajalahti and Kvalheim [70]. Analysis was performed using
SIMCA-P (v. 10.5, Umetrics, Umeå, Sweden) software. Figures
were drawn using Excel (2013, Microsoft Corp., Redmond,WA).
3. Results and discussion
Fig. 2 provides a representation of all the test samples inves-
tigated and reported here.
3.1. Spray drying
The spray dried formulation for this study, SD(ARG), was chosen
based on a series of unreported screening pre-tests. Prior to
this study, 14 prototype batches were manufactured using dif-
ferent spray drying process parameters and excipients. The
selected formulation, SD(ARG), was chosen because it had de-
sirable particle size (according to the light scattering and ACI
measurements), one of the highest yields and it was the least
hygroscopic (according to the DVS measurements) compared
to other batches in the pre-tests (results not shown). Leu was
shown to improve the yields and made the powders gener-
ally easier to handle and aerolize. Pure ARG (with no excipients)
was investigated as part of the pre-test regime but was found
to be highly hygroscopic and delivered zero yield as it was
unable to be recovered as dry particles from the collection
cyclone.
The yield for SD(ARG) used in this study was 50.5% (w/w).
The amount of aqueous solution for this batch of SD(ARG) was
400 g. When spray drying larger batch sizes (800 g), the yield
was noticed to be slightly better (approximately 55%). The
quality of powder, as measured by the powder characteriza-
tion tests described here, appeared consistent regardless of the
batch size.
3.2. Particle size and shape
Particle size (d10, d50 and d90) of the samples is represented
in Table 1. ARG(raw) had a large particle size (d50 = 72.7 μm,
n = 3) compared to the processed batches. SEM images seen in
Fig. 3 also provide a useful assessment of particle size.
Jet milling decreased the particle size of ARG substan-
tially. Ball milling did not seemed to further decrease the particle
size beyond that of the jet-milled samples but it changed the
shape of the particle according to SEM images (Fig. 4).
Mechanofusion did not have an effect on the particle size or
shape of the powders.
The particle sizes of the processed batches as indicated by
d50 were all generally satisfactory for pulmonary delivery, with
d50 being less than 5 μm, except for ARG1 and ARG5 which had
d50 values greater than 10 μm. d values are provided here as
a quality control tool to provide a screening indication only
to understand whether PSD is broadly within the respirable
range. It is worth noting that d values become inappropriate
as an indicator for the respirable range only when very low
density or very high density particles are used, or where shape
factors are extreme deviations from sphericity. None of these
are particularly relevant to any of the composite Leu par-
ticles here, so d values were argued to be acceptable just as
screening indicator for this work.
In addition, ARG1, ARG4 and ARG5 had large d90 values in
excess of 100 μm, and ARG2 and ARG7 had d90 values above
15 μm. SEM images (with magnification of 500× to 1000×) re-
vealed that there were large particles evident in the samples
ARG1, ARG2, ARG5 and ARG7 (Fig. 5) and it appeared possible
that these ball milling samples exhibited hard agglomerates
created during processing. Aggregates were occasionally also
present in other samples such as ARG4 due to hygroscopicity
of the materials.
In general, from SEM images the jet-milled and mechano-
fused samples appeared needle shaped,with individual needles
Table 1 – Parameters related to particle size, density and flowability.
Nomenclature d10 d50 d90 ρp ρt CI HR
ARG1 2.4 (0.33) 14.0 (1.17) 56.3 (3.66) 0.29 0.54 47.2 1.89
ARG2 1.0 (0.01) 4.6 (0.04) 16.7 (0.52) 0.25 0.36 31.5 1.46
ARG3 0.9 (0.00) 2.5 (0.02) 6.3 (0.07) 0.25 0.40 38.0 1.61
ARG4 1.0 (0.02) 3.1 (0.20) 178.2 (6.79) 0.29 0.45 35.9 1.56
ARG5 2.4 (0.31) 15.5 (2.53) 102.4 (6.71) 0.34 0.58 41.9 1.72
ARG6 1.0 (0.05) 2.4 (0.05) 5.9 (0.29) 0.26 0.45 41.1 1.70
ARG7 1.0 (0.02) 4.1 (0.23) 15.9 (0.96) 0.21 0.43 51.6 2.06
ARG8 0.9 (0.03) 2.1 (0.04) 4.6 (0.31) 0.22 0.33 34.1 1.52
ARG9 1.1 (0.01) 3.9 (0.05) 11.4 (0.12) 0.28 0.50 43.4 1.77
ARG10 1.3 (0.02) 2.9 (0.02) 6.7 (0.08) 0.28 0.45 39.0 1.64
ARG11 1.0 (0.01) 2.4 (0.03) 5.4 (0.10) 0.20 0.27 25.3 1.34
ARG12 1.0 (0.03) 2.7 (0.13) 6.5 (0.31) 0.17 0.23 25.0 1.33
JM(ARG) 1.0 (0.06) 2.8 (0.19) 14.9 (15.64) 0.16 0.21 21.7 1.28
SD(ARG) 1.2 (0.01) 2.3 (0.01) 4.3 (0.03) 0.11 0.16 32.0 1.47
ARG(raw) 12.4 (0.10) 72.7 (0.85) 232.0 (0.10) 0.63 0.82 24.0 1.32
d10 = particle diameter at which 10% of the particles have diameters that are greater or smaller than the d10 value, represented as mean (μm),
SD in parentheses (n = 3); d50 = particle diameter at which 50% of the particles have diameters that are greater or smaller than the d50 value,
represented as mean (μm), SD in parentheses (n = 3); d90 = particle diameter at which 90% of the particles have diameters that are smaller
than the d90 value, represented as mean (μm), SD in parentheses (n = 3); ρp = poured density (g/ml) (n = 1); ρt = tapped density (g/ml) (n = 1);
CI = Carr index (n = 1); HR = Hausner ratio (n = 1).
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approximately 1 × 3 to 10 μm. Ball-milled samples appeared
more irregularly shaped, with lower aspect ratio than the
needles.Thus the mechanofusion process appeared less shape
modifying than the ball milling process. Spray dried samples
(SD(ARG) and ARG10) appeared as spherically aggregated par-
ticles with individual particles approximately 2 μm diameter.
3.3. Density and flowability
Bulk and tapped density and flowability of the batches are rep-
resented in Table 1. Unmodified ARG was the most dense, while
SD(ARG) had the lowest density. When SD(ARG) was
mechanofused with MS (ARG10), the density increased sub-
stantially. Jet milled samples started with low density, and after
further processing (BM or MF), the densities also increased.
HR and CI are both proposed as measures of the flow prop-
erties of powders. HR of <1.25 should indicate a powder that
is free flowing, whereas >1.25 indicates poor flow ability. Simi-
larly, the smaller CI, the better the flow properties. It has
previously been reported that the apparent relationship between
particle size and flow behavior for micronized highly cohe-
sive powders is generally not observed in CI and HR values [37].
The current work similarly suggests no consistent pattern to
support this, and it appears that cohesivity is so high that
tapping is not sufficient to measurably alter the density and
provide a good indicator of flow. Consequently, cohesion was
also measured using the Freeman FT4 rheometer shear cell.
3.4. Cohesion
Unmodified ARG, due to its larger particle size, had the lowest
cohesion (Table 2). It was noted that the cohesion values for
powders processed with MS were relatively lower than cohesion
values for corresponding formulations with Leu.Thus MS was
deemed to reduce the interaction between ARG particles better
than Leu, potentially by its reported capability to better cover
the particle surface with a hydrophobic layer [71].
Lubrication of dry coating of particle surface has been dem-
onstrated to modify the surface energy of pharmaceutical
powders [37,72,73]. Jet-milled batches had higher cohesion than
mechanofused and ball-milled batches. It was observed that
further processing with lubricant decreased the cohesion (ex-
cluding ARG8), this effect being most pronounced with ARG9
containing 20% of MS.
3.5. In vitro powder aerolization
In vitro powder aerolization results are represented in Table 2.
The emitted powder doses (EP) for all formulations were above
60%, and mostly between 75 and 90%.Thus, powders were gen-
erally well fluidized and emitted from the capsule and the
device.
In each case, the theoretical amount of excipients was taken
into account when calculating FPD and FPF. For instance SD(ARG)
included only 40% ARG, so the actual amount of ARG was only
less than 7 mg (of approximately 20 mg weighed into the
capsule). However, its EP was almost 95% and total powder FPF
wasmore than 90%, indicating excellent aerosolization behavior.
Batches ARG3, ARG6, ARG8 and ARG11 had the highest FPD
values providing 9–10 mg of ARG on the filter paper ACI stage.
In general,mechanofused and co-jet milled samples gave much
higher FPF and FPD values than ball-milled samples.There were
no consistent differences between the used excipient (MS or
Leu) and FPD or FPF, with both providing improved aerosol-
ization. The addition of MS or Leu in jet milling gave a
substantial improvement compared to pure JM(ARG).
Fig. 3 – SEM images of raw materials. (A) and (D) L-arginine, (B) and (E) leucine, (C) and (F) magnesium stearate. (A, B, and C)
Magnification 100×, (D, E, and F) Magnification 500×. Scale bar in the images. “Holes” in (C) are due to the carbon tape, not
related to magnesium stearate sample.
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Fig. 4 – SEM images of the samples. (A) ARG1, (B) ARG2, (C) ARG3, (D) ARG4, (E) ARG5, (F) ARG6, (G) ARG7, (H) ARG8, (I) ARG9,
(J) ARG10, (K) SD(ARG), (L) JM(ARG), (M) ARG11, and (N) ARG12. Magnification 5000×, scale bar in the images.
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According to the FPD results, the best performing batches
(FPD > 9 mg) were ARG3, ARG6, ARG8 (all mechanofused) and
ARG11 (jet milled with Leu). These were substantially better
than most other formulations, which had FPD generally below
4 mg.
Standard deviation (SD) for FPD values indicated good mea-
surements repeatability (n = 3). Only ARG4 had an SD over 1
and this may be explained with high d90 value referring to the
observed large particles in the sample.
As expected when particle size (d50) decreased, generally
FPF and FPD increased and vice versa. ARG1 and ARG5 had sig-
nificantly larger particle sizes (d50) than the other batches and
consequently demonstrated low FPF. ARG10 was an excep-
tion as the particle size of this formulation was small but FPF
is poor since the batch showed relatively high hygroscopicity
(Mt = 22.77%). It can be also stated that there was no observ-
able relationship between density-derived flowability (CI and
HR) and FPF.
In this study, the jet-milled needle-shaped particles were
observed to achieve good dispersion during the actuation. Louey
et al. [74] studied the effect of jet milling and spray drying of
mannitol particles for pulmonary delivery and concluded that
the aerosol dispersion of angular jet-milled particles was not
as efficient as spherical spray-dried particles, with spray-
dried particles producing higher values of FPF. In this study,
the spray dried particles give excellent aerosolization but are
limited in FPF due to the amount of excipient required.
3.6. Dynamic vapour sorption and hygroscopicity
DVS results are expressed as the weight increase from 0% RH
to 75% RH (Mt) and values are represented in Table 2.The most
hygroscopic samples were both spray dried samples: ARG10
(Mt = 22.77%) and SD(ARG) (Mt = 24.38%). Any moisture protec-
tion by mechanofusion with MS was not detectable based on
the conditions used in this test.The least hygroscopic samples
were ARG4, ARG2, ARG8, ARG11, ARG7 and ARG9 (Mt 15.57–
16.49%). For the rest of the samples,Mt was between 19.14 and
20.01%.
Fig. 5 – SEM images of the samples. (A) ARG4, (B) ARG5, (C) ARG5. (A and B) Magnification 500×, (C) magnification 20,000×,
scale bar in the images.
Table 2 – Parameters related to in vitro aerolization, cohesion and moisture uptake.
Nomenclature Process Excipient(s) FPF FPD ED EP Cohesion Mt
ARG1 JM→BM MS 8.47 (0.86) 1.51 (0.01) 17.90 (1.73) 87.14 (6.86) 1.45 19.73
ARG2 JM→BM Leu 26.77 (0.48) 3.94 (0.29) 14.70 (0.97) 90.86 (1.84) 1.54 16.26
ARG3 JM→MF MS 69.51 (1.97) 10.54 (0.74) 15.16 (0.89) 73.56 (1.49) 1.78 19.76
ARG4 JM→MF Leu 57.49 (10.28) 8.13 (1.56) 14.13 (0.76) 86.29 (1.67) 3.07 15.57
ARG5 JM→BM MS 4.00 (0.68) 0.78 (0.16) 19.35 (0.77) 100.17 (0.28) 1.24 19.65
ARG6 JM→MF MS 63.40 (5.53) 9.88 (0.27) 15.64 (0.90) 77.83 (1.14) 1.28 19.78
ARG7 JM→BM Leu 26.70 (0.61) 4.02 (0.16) 15.08 (0.91) 91.82 (1.97) 2.38 16.38
ARG8 JM→MF Leu 67.02 (3.09) 9.98 (0.14) 14.91 (0.65) 84.40 (3.60) 3.88 16.31
ARG9 JM→MF MS20% 30.13 (0.62) 3.75 (0.18) 12.46 (0.76) 76.41 (2.63) 1.08 16.49
ARG10 SD→MF Leu, IM→MS 18.24 (1.63) 1.29 (0.08) 7.10 (0.21) 91.59 (1.74) 10.88 22.77
ARG11 JM Leu 62.15 (0.60) 9.32 (0.40) 15.01 (0.78) 85.24 (3.02) 3.13 16.35
ARG12 JM MS 49.37 (1.92) 7.77 (0.54) 15.76 (1.40) 79.30 (1.98) 2.54 19.14
JM(ARG) JM – 48.88 (3.85) 5.86 (0.68) 11.98 (0.71) 60.71 (4.31) 3.41 20.01
SD(ARG) SD Leu, IM 90.21 (4.89) 6.88 (0.14) 7.64 (0.38) 94.71 (2.44) 3.70 24.38
ARG(raw) – – n/a n/a n/a n/a 0.72 19.99
MS = magnesium stearate; Leu = leucine; IM = isomalt; JM = jet milling; BM = ball milling; MF = mechanofusion; EP = emitted powder (%), rep-
resented as mean, SD in parentheses (n = 3); FPD = fine particle dose (mg), represented as mean, SD in parentheses (n = 3); FPF = fine particle
fraction (%), represented as mean, SD in parentheses (n = 3); ED = emitted dose (mg), represented as mean, SD in parentheses (n = 3); Cohe-
sion = cohesion measured using FT4 (kPa) (n = 1); Mt = moisture uptake (%) (n = 1); n/a = not available.
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Based on the standards described by Newman et al. [75],
all of the batches were deemed to be very hygroscopic (>15%,
w/w, of moisture uptake) (with no batches being classified as
extremely hygroscopic (>25%, w/w, moisture uptake).
Most of the batches that contained Leu had less moisture
absorbed (lower Mt values) than batches with MS. However,
ARG9, which included 20%MS, had lower moisture uptake than
the other batches with MS, including ARG3 which was pro-
cessed exactly the same as ARG9,with the only difference being
the amount of MS.Thus, a higher amount of MS used seemed
to protect ARG better from moisture.
Interestingly, there was no observed correlation between Mt
and FPD or FPF.Mt did not correlate with cohesion either, even
though it is known that moisture can increase cohesion of fine
particles. This indicated that moisture uptake was not of a
nature to affect the in vitro powder aerosolization perfor-
mance. This could be due to moisture uptake being internal
rather than collecting at the surface.
3.7. Principal component analysis
PCA was established based on the parameters described in
Section 2.2.11. The R2 (correlation coefficient) value with two
principal components in themodel was 67.3% and Q2 value (test
set validation coefficient) was 54.5%, indicating a good model.
Formulation batches with similar behavior according to result
parameters (such as d10 or FPD) appear in the same area in
the score scatter plot (Fig. 6A). The result parameters that
account for the distribution on the score plot are plotted in the
loading plot (Fig. 6B and 6C). For instance batches ARG1 and
ARG5 are plotted in the right side of the score plot due to their
similar d50 values. Thus the loading plot reveals covariance
among variables and can be used to interpret patterns ob-
served in the score plot.
The results of this PCA suggest that, if FPF and FPD were
emphasized as the most important parameters for the formu-
lation, batch ARG8 would be the preferred candidate, with
batches ARG3,ARG6 and ARG11 as close alternative candidates.
The optimized co-spray dried batch produced particles with
a suitable particle size distribution and excellent in vitro
aerolization performance. However, due to the hygroscopic-
ity of ARG, the composition was diluted substantially and so
achieving high dose delivery of ARG using a spray drying ap-
proach may be challenging. In this study excipients (40% (w/
w) isomalt and 20% (w/w) Leu) were used for spray drying when
only 2% (w/w) of MS or 20% (w/w) of Leu was needed for jet-
milling, mechanofusion and ball milling. Thus the amount of
ARG in the final formulation is substantially different. Fur-
thermore, it will need to be established from a toxicology and
hence regulatory basis which spray drying excipients (such as
isomalt) are suitable for (pulmonary) delivery.
Jet milling produced micronized ARG particles but co-jet
milling with suitable additives was shown to create particles
that were more suitable for high-dose efficient aerosolization.
In this case, a much lower excipient load more than compen-
sated for slightly lower aerosolization efficiency relative to
optimized spray-drying.As a subsequent step,mechanofusion
formulations appeared to provide ARG with more protection
from moisture, and this may be due to a more coherent par-
ticle coating than with co-jet milling. Ball milling was studied
as a potential alternative, but substantially reduced the in vitro
aerolization performance,which appeared to result from caking
of the powders as seen in SEM images (Fig. 4).
In this study, the aerosolization parameters were calcu-
lated from gravimetric data – an approach that was valid
because no separate carrier particles were incorporated in the
formulation. Nevertheless, the formulations used in this study
contained different amounts excipients which might lead to
different amounts/ratios depositing to different parts of the
lungs if the excipients were not evenly distributed in the for-
mulation.With respect to spray drying, during spray drying of
a solution the formation of particles from droplets of a ho-
mogeneous solution very rarely can provide any credible
Fig. 6 – PCA plots based on measured properties of the
batches. (A) Score plot, (B) loadings plot, (C) close-up from
(B).
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mechanism for the separation of those homogeneously dis-
tributed components, and so for spray drying there would be
no substantial partitioning expected. Mechanofusion has been
previously reported for similar studies [37] and is regarded to
create host–guest structures with the excipient additives, such
as MS or Leu used here, forming robust complete or partial
coating layers, and so partitioning is not expected. Both MS and
Leu are soft lamellar waxy solids, which readily adhere to host
surfaces. Furthermore, with MS, formulations comprised only
2% (w/w) of excipient, and so any segregation/partitioning was
most unlikely to have measurable impact on the data outside
the expected noise in the data. For the ball milled and co-jet
milled samples, such host–guest structures are also ex-
pected, but there is less experience in the literature to support
this, and so for the cases with Leu where 20% is added, there
is a degree of greater uncertainty here, but given that the com-
position was 20% (w/w) excipient, again any absolute error here
was likely small, and this would have affected samples ARG1,
ARG4,ARG7-ARG9 andARG11. On reviewing the FPD data,ARG8
and ARG11 were the most prone to this issue, although ARG8
was mechanofused which would mean that it was arguably
less prone to partition.
The prevalence of TB is highest in regions classified as cli-
matic zones III, IV, and IVb by the International Commission
for Harmonization of Laboratory Data [76]. This means that a
formulation for this indication would need to function effec-
tively during administration at elevated humidity conditions.
Protection from humidity during storage can be achieved by
foil wrap packaging, although extra cost for packaging would
incur. Further studies should test whether the short term high-
humidity exposure of the powder during actuation would
significantly compromise aerosolization.
An oral dose for ARG in the study by Ralph et al. [16] was
as high as 6 g. Amounts this high are most likely impractical
by inhalation. Traditionally, in order for a drug to be consid-
ered for inhalation therapy, it needs to be therapeutically
effective in the low microgram or the milligram range for a
single dose [77]. However, studies have shown from other areas
that inhaled doses may be an order of magnitude reduced rela-
tive to oral, and this may be reduced further for a highly efficient
inhaled formulation [3].With the development of new inhaler
technologies, this quantity may increase substantially [78] and
limitation may be more related to patient tolerance of the
inhaled mass. Surprisingly large amounts (total 112 mg) of
spray-dried tobramycin powder were administered to CF pa-
tients using Novartis T-326 Inhaler. This formulation has been
shown to be well tolerated in patients [79].
In our study, we have shown that more expensive particle
engineering technologies such as spray drying or emulsion/
precipitation may not be necessary for producing a readily
aerosolizable ARG formulation, capable of aerosolizing milli-
gram doses at high respirable fraction efficiencies. Increased
powder bulk densities, such as achieved by mechanical powder
coating, may also aid in producing suitable metred unit
doses.
In addition to total dose, drug targeting should also be con-
sidered. For TB, the mycobacteria exist in macrophages in the
lungs. The question rises, should ARG be targeted in a format,
perhaps employing extended release, to access the mac-
rophages to gain better response?
4. Conclusions
Suitable in vitro aerolization properties were achieved with
several prototype DPI formulations of ARG. Co-Jet milling or
jet milling combined with mechanofusion to produce coated
ARG particles was the most promising manufacturing method.
Spray dried batches gave excellent aerosolization but re-
quired dilution with excipient such that theARG dose was lower.
In addition, powders manufactured using spray drying were
sensitive to moisture.
The excipients magnesium stearate and L-leucine were suit-
able coating additives for the formulation. However, the
hygroscopicity of ARG might still be a challenge even when
using these protective excipients. It also remains to be seen
what will be the required dose for ARG and if this high demand
be fulfilled when utilizing a conventional DPI.
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